C

    Crispr Therapeutics AG (CRSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $56.98
    -0.74 (-1.28%)

    Market Cap: $5.58B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    +77.19%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.05
    Range$-1.50 - $-0.46
    17 analysts
    EPS Revisions
    9
    0
    7d
    9
    2
    30d
    EPS Estimate Drift
    90d ago$-1.18-12.4%
    60d ago$-1.18-12.2%
    30d ago$-1.19-12.9%
    7d ago$-1.05+0.0%
    Current$-1.05
    Revenue Consensus
    $17M
    Range$0 - $77M
    15 analysts
    Dec 31, 2026
    EPS Consensus$-0.98
    Range$-2.37 - $0.28
    18 analysts
    Revenue Consensus
    $13M
    Range$-16580350 - $136M
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.98---
    Sep 26EST
    		-$-1.05---
    Jun 26
    		$-0.94$-1.10+14.55%Beat+27.1%
    Mar 26
    		$-1.28$-1.23-4.07%Miss+19.0%
    Dec 25
    		$-1.37$-1.23-11.38%Miss-211.4%
    Sep 25
    		$-1.17$-1.29+9.30%Beat-15.8%
    Jun 25
    		$-1.29$-1.40+7.86%Beat+13.4%
    Mar 25
    		$-1.58$-1.28-23.44%Miss-10.5%
    Dec 24
    		$-0.44N/A+62.89%Beat-140.0%
    Sep 24
    		$-1.01$-1.40+27.86%Beat+28.4%
    Jun 24
    		$-1.49$-1.43-4.20%Miss-52.0%
    Mar 24
    		$-1.43$-1.33-7.52%Miss-113.4%
    Dec 23
    		$1.10$0.05+2100.00%Beat+178.0%
    Sep 23
    		$-1.41$-1.95+27.69%Beat+37.1%
    Jun 23
    		$-0.98N/A+53.33%Beat+59.2%
    Mar 23
    		$-0.67N/A+59.15%Beat+71.1%
    Dec 22
    		$-1.41$-2.30+38.70%Beat+23.4%
    Sep 22
    		$-2.24$-2.24+0.00%Beat-34.1%
    Jun 22
    		$-2.40$-2.21-8.60%Miss-125.4%
    Mar 22
    		$-2.32$-1.97-17.77%Miss-53.6%
    Dec 21
    		$-1.84$-1.78-3.37%Miss-22.7%
    Sep 21
    		$-1.67$-1.76+5.11%Beat-26.5%
    Jun 21
    		$9.44$3.12+202.56%Beat+826.2%
    Mar 21
    		$-1.51$-1.47-2.72%Miss-31.3%
    Dec 20
    		$-1.50$-1.27-18.11%Miss-394.1%
    Sep 20
    		$-1.32$-1.19-10.92%Miss-155.0%
    Jun 20
    		$-1.30$-0.99-31.31%Miss-28.7%
    Mar 20
    		$-1.15$-1.04-10.58%Miss-23.7%
    Dec 19
    		$0.51$-0.63+180.95%Beat+155.4%
    Sep 19
    		$2.40$1.79+34.08%Beat+324.3%
    Jun 19
    		$-1.01$-0.90-12.22%Miss-23.2%
    Mar 19
    		$-0.93$-0.90-3.33%Miss-50.0%
    Dec 18
    		$-0.92$-0.78-17.95%Miss-27158.8%
    Sep 18
    		$-1.07$-0.74-44.59%Miss-72.6%
    Jun 18
    		$-0.82$-0.64-28.13%Miss-46.4%
    Mar 18
    		$-0.62$-0.67+7.46%Beat-14.8%
    Dec 17
    		$0.00N/A+100.51%Beat-99.8%
    Sep 17
    		$-0.62$-0.60-3.33%Miss-67.6%
    Jun 17
    		$-0.56$-0.62+9.68%Beat-
    Mar 17
    		$-0.54$-0.65+16.92%Beat-
    Dec 16
    		$1.42$-0.49+389.80%Beat-
    Sep 16
    		$-0.37$-0.38+2.63%Beat-

    Key Metrics

    Valuation
    P/E Ratio-11.97EV/EBITDA14.16x
    Price/FCF-14.81xFCF Yield-6.75%
    Profitability
    Profit Margin0.00%Operating Margin-1128.00%
    ROE-26.10%ROIC-19.21%
    Financial Health
    Debt/Equity0.34xInterest CoverageN/A
    Current Ratio17.85xQuick Ratio17.85x
    Trading Statistics
    Beta1.74Avg Volume1.50M
    52-Week High$78.4852-Week Low$44.12

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$58.17
    SMA 20$55.79
    SMA 50$53.56
    SMA 200$53.16
    EMA 10$57.57
    EMA 20$56.01
    EMA 50$54.07
    EMA 200$53.15

    MACD

    Line: 1.88Signal: 1.72Hist: 0.17

    ADX

    ADX: 29.9+DI: 26.5-DI: 15.6

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down4.0
    PSAR$55.49

    Bollinger Bands

    Upper Band$61.66
    Lower Band$49.92
    %B Position2105%(Upper)
    Band Width0.60

    RSI (14-Day)

    Neutral
    54.5

    Momentum Oscillators

    Stoch %K58.0
    Stoch %D66.0
    Williams %R-51.7
    ROC (10d)5.0%
    Momentum2.70
    CCI (20d)29.2
    MFI (14d)60.3

    Volatility Measures

    ATR (14d)$2.66(4.7%)
    StdDev (20d)2.94
    Hist Vol65.5%(High)

    Volume Flow

    VWAP$56.87
    OBV22.9M
    AD Line-1.7M
    CMF (20d)0.113

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio0.8x
    VWMA (20d)$56.52

    Pivot Points

    R3$61.30
    R2$60.33
    R1$59.03
    Pivot Point$58.06
    S1$56.76
    S2$55.79
    S3$54.49

    Advanced Oscillators

    TSI19.06
    Ultimate Osc51.0
    KST127.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$10.18M$1.46M$864,000$889,000$892,000$865,000$35.69M$602,000$517,000$504,000$201.21M$0
    Cost of Revenue$0$0$59.36M$0$0$0$4.15M$0$0$0$20.00M$0
    Gross Profit$10.18M$1.46M$864,000$889,000$892,000$865,000$35.69M$602,000$517,000$504,000$201.21M$0
    Operating Expenses$127.45M$131.71M$155.63M$132.95M$230.22M$149.29M$100.28M$110.73M$151.78M$141.09M$131.62M$132.41M
    R&D$69.63M$68.57M$83.53M$58.90M$166.15M$72.48M$71.74M$82.16M$80.17M$76.17M$95.14M$90.70M
    SG&A$17.55M$17.18M$18.40M$16.93M$18.92M$19.30M$18.12M$17.42M$19.48M$17.95M$16.48M$18.29M
    Operating Income$-117,269,000$-130,248,000$-154,764,000$-132,059,000$-229,324,000$-148,424,000$-64,589,000$-110,130,000$-151,260,000$-140,587,000$69.58M$-132,411,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-90,194,000$-122,092,000$-129,999,000$-105,822,000$-207,257,000$-134,887,000$-36,611,000$-85,066,000$-125,121,000$-115,867,000$89.58M$-111,740,000
    Income Tax Expense$960,000$839,000$614,000$619,000$1.29M$1.11M$700,000$876,000$1.29M$724,000$233,000$412,000
    Net Income$-91,154,000$-122,931,000$-130,613,000$-106,441,000$-208,549,000$-135,996,000$-37,311,000$-85,942,000$-126,408,000$-116,591,000$89.35M$-112,152,000
    EBITDA$-85,914,000$-117,773,000$-124,338,000$-101,389,000$-202,608,000$-130,151,000$-31,769,000$-80,327,000$-120,276,000$-111,034,000$94.48M$-106,815,000
    EBIT$-90,194,000$-122,092,000$-129,999,000$-105,822,000$-207,257,000$-134,887,000$-36,611,000$-85,066,000$-125,121,000$-115,867,000$89.58M$-111,740,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRSP

    News

    CRISPR Therapeutics Shares Advance 5.8% Ahead of CTX310 Results Release

    CRISPR Therapeutics (NASDAQ:CRSP) saw its shares climb 5.8% ahead of the anticipated release of CTX310 clinical trial results on August 28th. The company holds a strong financial position with $2.36 billion in cash and securities, supporting its continued research and development despite being cash flow negative. Analysts from Citizens maintain an "Outperform" rating with an $80 price target, highlighting the potential for CTX310 as a "truly differentiated, one-time therapy" for severe triglyceride and cholesterol conditions.

    TechStock²•8/25/26•
    Neutral

    CRISPR Therapeutics (NASDAQ:CRSP) Earns Market Outperform Rating from Citizens Jmp

    Citizens Jmp has reissued a "market outperform" rating for CRISPR Therapeutics (NASDAQ:CRSP) and set an $80 price target, suggesting a 40.15% upside. This positive outlook aligns with a "Moderate Buy" consensus rating from analysts, though the stock recently reported a quarterly loss of $0.94 per share. Institutional investors hold a significant 69.20% stake in the company.

    MarketBeat•8/25/26•
    Bullish

    CRISPR Therapeutics (CRSP) Rallies On Pipeline Focus, Is The 73% Discount Too Hard To Ignore?

    CRISPR Therapeutics (CRSP) has seen a recent rally, with its stock closing at $59.50, reflecting a 27.85% return over the past month. Despite a 5-year decline of 51.94%, the company, which focuses on gene-based medicines, is estimated by a Simply Wall St DCF model to have an intrinsic value of $220.94, suggesting a 73.1% discount. The article explores whether this significant discount signals an investment opportunity or justifies market caution due to the company's ongoing losses and long development timelines for its pipeline.

    Sahm•8/22/26•
    Somewhat-Bullish

    CRISPR Therapeutics (CRSP): Orbis-led investors disclose 5.6% ownership stake

    Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have disclosed a combined beneficial ownership of 5,449,161 shares, or 5.6%, of CRISPR Therapeutics AG (CRSP) Common Stock as of June 30, 2026. Orbis holds the vast majority of these shares with sole voting and dispositive power, while Allan Gray Australia holds a smaller portion, also with sole voting and dispositive power. Both entities disclaim being part of a group for beneficial ownership purposes.

    Stock Titan•8/14/26•
    Neutral

    Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP)

    CRISPR Therapeutics (CRSP) reported improved Q2 2026 results with rising revenue and a narrower net loss, offering some relief regarding its cash burn. While these results strengthen the company's position, the market views them as helpful but not thesis-changing, as the core investment narrative still hinges on the eventual success of its gene-editing pipeline and commercial uptake. Investors should consider the impact of sustained losses on future funding needs and weigh various fair value estimates.

    Sahm•8/13/26•
    Somewhat-Bullish

    Frequently Asked Questions About CRSP

    Does CRSP pay dividends?
    Crispr Therapeutics AG (CRSP) does not currently pay a regular dividend.
    What is CRSP's market cap?
    Crispr Therapeutics AG (CRSP) has a market capitalization of $5.58B with a current stock price of $56.98.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In